Cardiometabolic Health Disparities in Hispanic Americans
Veronica Vital, Ph.D., RN
Alexandra Salcedo, RDN
Nutrition and Cardiovascular Mortality
During this webinar, internationally-recognized cardiologist Kim A. Williams, Sr., MD, discussed the impacts of nutrition on cardiovascular mortality, as well as common-sense nutritional approaches that have been proven to reduce CV burden in high-risk cardiometabolic patients.
MD, PhD, FRCP, FACC
Cardiac TTR Amyloidosis: Contemporary Diagnosis and Therapy
In this webinar, Prem Soman, MD, PhD, Associate Professor of Medicine and Director of the Cardiac Amyloidosis Center at the University of Pittsburgh Medical Center, reviews the diagnosis and treatment for ATTR-CM.
Evolving Lipid Management
CMHC co-chair Christie M. Ballantyne, MD, will discuss the topic of CVD prevention in the cardiometabolic patient in light of the recently released cholesterol and comprehensive primary prevention guidelines. Dr. Ballantyne will also discuss the evolution of lipid therapy and lipid targets, including the role of Lp(a) and hypertriglyceridemia in treatment and prevention, as well as lifestyle and obesity management.
The Importance of Navigating Female Cardiometabolic Care
Dr Pam Taub will discuss the unique risk factors and challenges faces by women in cardiometabolic health. As Associate Professor of Medicine in the Division of Cardiovascular Medicine at the University of California San Diego, Dr. Taub also serves as Director of the Step Family Foundation Cardiovascular Rehabilitation and Wellness Center, focusing on best practices to actively engage patients and the community in prevention of cardiovascular disease.
The Emerging Role of Technology in Type 2 Diabetes Management
CMHC faculty and diabetes expert Dr. Anne L. Peters discusses why we need to look beyond HbA1c as a target, particularly for patients with cardiovascular risk, and how technology can help improve outcomes. Dr. Peters also discusses practical steps and strategies to optimize the use of technology, including CGM devices, for diabetes management in everyday practice.
Cardio-Renal Benefits with GLP-1 RAs and SGLT-2 Inhibitors
CMHC Chairs George Bakris, MD, Professor of Medicine and Director of the ASH Comprehensive Hypertension Center at University of Chicago Medicine and Jay S. Skyler, MD, Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology, Diabetes, & Metabolism at University of Miami Miller School of Medicine, review the recent data about the cardio-renal benefits with GLP-1 RAs and SGLT-2 inhibitors in patients with diabetes, and what they mean to the practicing clinician.
The Management of Hypertriglyceridemia
CMHC Chair Robert H. Eckel, M.D, Charles A Boettcher II Endowed Chair in Atherosclerosis, Emeritus Professor of Medicine in the Division of Endocrinology, Metabolism and Diabetes and the Division of Cardiology, and Professor of Physiology and Biophysics at the University of Colorado School of Medicine Anschutz Medical Campus will review the potential causes and considerations in patients with hypertriglyceridemia (HTG), including those with severe HTG, and appropriate management.
NASH in a Dash
Dr. Christos S. Mantzoros will discuss the increasing prevalence and clinical significance of non-alcoholic steatohepatitis (NASH), what leads to NASH and its complications, current treatments, and what the future holds. As Professor of Medicine at Harvard Medical School and Adj. Prof. at Boston University School of Medicine, Dr. Mantzoros also serves as the Chief of Endocrinology, Diabetes and Metabolism at the Boston VA Healthcare System and the Director of Human Nutrition at Beth Israel Deaconess Medical Center.
Coronary Artery Disease in South Asians
Navin C. Nanda, MD, Distinguished Professor Of Medicine and Cardiovascular Disease at the University of Alabama at Birmingham, and President of International Society of Cardiovascular Ultrasound (ISCU), discusses the prevalence, risk factors, as well as screening and treatment of CAD in the South Asian population.
Emerging Approaches to LDL-C Lowering
CMHC chair and renowned lipids expert Christie M. Ballantyne, MD, reviews the rationale and evidence for emerging LDL-C lowering agents, including inclisiran and bempedoic acid, as well as their potential practice implications in the near future.
Challenge of Cardiovascular Risk Reduction in Racial and Ethnic Minorities
CMHC Senior Planning Committee member Keith C. Ferdinand, MD, reviews the impact of ethnicity and race in CVD risk, and the increased risk for cardiometabolic disease in certain ethnic minorities.
The Novel Coronavirus: Going Viral
Interview with Gregory Poland, MD, Distinguished Investigator of the Mayo Clinic, and Director of the Mayo Vaccine Research Group, on what physicians need to know about the novel coronavirus outbreak.
Antithrombotic Therapy In Diabetes Patients
CMHC Senior Planning Committee member and renowned physician and researcher, discuss the results of THEMIS and THEMIS-PCI Studies and their clinical practice implications.
Lifestyle Approaches to Weight Reductions: Challenges and Opportunities
Professor and Vice Chair for Clinical Programs University of Alabama at Birmingham Dept. of Nutritional Sciences, discussed the challenges faced by physicians in counseling their patients while providing practical tips that can help curb the obesity epidemic.
Therapeutic Carbohydrate Restriction for Type 2 Diabetes
Amy McKenzie, PhD
DO, MS, ACSM – CEP, FNLA, FOMA
During this webinar Drs. Amy McKenzie and Sarah Hallberg discussed both the evidence for and implementation of carbohydrate restriction for patients with type 2 diabetes.
Use of Continuous Glucose Monitoring in Cardiovascular and Pulmonary Rehabilitation
CMHC chair Anne Peters, MD, discusses the role of CGM in optimizing glucose control, exercise and nutrition in diabetes patients undergoing cardiopulmonary rehabilitation
REDUCE-IT: Data, Cost-Effectiveness, and Guidelines
CMHC Senior Planning Committee member and renowned physician and researcher Dr. Deepak Bhatt, will overview the recent advances in addressing residual atherosclerotic risk. While hypercholesterolemia is an important, modifiable risk factor of ASCVD, residual risk may be present after optimization of LDL-C levels. Recent results with icosapent ethyl, as demonstrated by the REDUCE-IT trial, have shown that this agent can significantly reduce atherosclerotic events in high-risk hypertriglyceridemic patients with clinical ASCVD or type 2 diabetes and additional markers of increased risk. Dr. Bhatt, one of the principal investigators of the REDUCE-IT trial, will review the results of this trial and its clinical practice implications.